XOMA and LAVA amend purchase agreement with lower cash offer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement
October 17, 2025 11:45 AM EDT- Amendment includes finalized cash amount and updated CVR terms for tender offer
- LAVA announces new date for extraordinary general meeting of shareholders
EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Penn., Oct. 17, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (XOMA Royalty) (Nasdaq: XOMA) and LAVA Therapeutics N.V. (LAVA) (Nasdaq: LVTX) today announced that they have reached an agreement to amend their previously announced definitive share purchase agreement (the Purchase Agreement, and such amendment, the Amendment). Â
Under the Amendment, LAVA... More
